Abstract CD3f is a subunit of the CD3 molecule that, until recently, appeared restricted to T cells and natural killer cells. However, experimental studies have demonstrated a role of CD3f in dendritic outgrowth in the visual system as well as in synaptic plasticity. Given the increasing evidence for uncharacteristic recapitulation of neurodevelopmental processes in neurodegenerative diseases, in this study, we evaluated brains from subjects with Parkinson's disease and Lewy body dementia for evidence of aberrant CD3 expression. Our data shows marked CD3f in association with the a-synuclein containing pathological lesions, i.e., Lewy bodies and Lewy neurites, in the brains of subjects with Parkinson's disease and Lewy body dementia. This finding raises the novel concept of CD3 dysregulation in these disorders as a pathogenic factor and also furthers the increasing evidence that the recall of aberrant neurodevelopmental processes underlies the pathogenesis of neurodegenerative diseases.
Introduction
Evidence of similarities in molecular signaling between neuroectodermal cells and the immune system is accumulating, which in turn suggests novel neuronal functions for molecules previously restricted to the immune system (Boulanger and Shatz 2004; Baudouin et al. 2008) . It is already established that dendritic development is regulated by a number of factors, such as neuronal activity (Lohmann et al. 2002) , diffusible molecules (Polleux et al. 2000) , and signaling molecules (Fink et al. 2003) , processes that are also involved in the differentiation and function of immune cells. The diffusible signaling molecules, semaphorins and slits, for example, involved in dendritic outgrowth, are required for the maturation, migration, and activation of T lymphocytes and follicular dendritic cells (Polleux et al. 2000) . Such commonalities emphasize the similarities of such ostensibly divergent cellular phenotypes as neurons and lymphocytes.
Conversely, CD3f, a subunit to the CD3 antigen and a transmembrane signaling protein that, until recently, had only been characterized in T lymphocytes and natural killer cells (Lanier 2001; Pitcher and van Oers 2003) , has been implicated in the development of retinogeniculate projections in the visual system and synaptic plasticity (Huh et al. 2000; Barco et al. 2005) . These findings raise the possibility of a fundamental neurodevelopmental role of CD3f, and therefore, the possibility that abnormalities in CD3 transcription, translation, or expression with age or disease may be involved in neurological diseases.
To address the role of CD3 in human neurologic disease, we examined brains of subjects with Parkinson's disease and Lewy body dementia for CD3 expression.
Materials and methods
Tissue from six cases with Lewy body dementia (age range 59-82), six with Parkinson's disease (age range 53-81), and four control cases (age range 67-86) were fixed in either 10% formalin or methacarn (methanol/chloroform/ acetic acid, 60:30:10 by volume). Following fixation tissue was embedded in paraffin and 6 lm thick sections were mounted on silane-coated slides (Sigma, St. Louis, MO). Sections were then hydrated through descending ethanol. Endogenous peroxidase activity was eliminated by incubation in 3% H 2 O 2 in Tris-buffered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 30 min. To reduce non-specific binding, sections were incubated for 30 min with 10% normal goat serum (NGS) in TBS. After rinsing briefly with 1% NGS, sections were incubated overnight with primary antibody, CD3f (rabbit, Dako North America, Carpinteria, CA) (Zhan et al. 2005) or a-synuclein (mouse; Abcam, Cambridge, MA) (Zhu et al. 2006) . As previously described (Smith et al. 1994a, b) , cells were stained with the peroxidase antiperoxidase method (Sternberger 1986 ) using 3,3 0 -diaminobenzidine (DAB) as a chromogen (Dako Corporation, Carpinteria, CA, USA).
Results
Brains from six Lewy body dementia subjects showed a-synuclein pathology in the form of Lewy bodies and Lewy neurites, in the brainstem and neocortex, indicative of Lewy body dementia, and six brains from subjects with the clinical diagnosis of Parkinsonism and Lewy bodies within nigral dopaminergic neurons at autopsy (i.e., Parkinson's disease) were also examined. Pathology was highlighted using a-synuclein immunohistochemistry as described previously (Zhu et al. 2006) .
CD3 immunohistochemistry was remarkable for widespread immunoreactivity limited only to brains of subjects with Parkinson's disease and Lewy body dementia. The immunoreactivity showed precise overlap with a-synuclein pathology, reacting with brainstem and neocortical Lewy bodies and Lewy neurites, including the CA-2,3 linear dystrophic neurites characteristic of Lewy body dementia (Fig. 1) . No staining of histologically unaffected neurons was apparent nor was there labeling of neurons in control brain sections.
Discussion
In this study, we noted a precise overlap between immunoreactivity for CD3 and that for a-synuclein in cases of Lewy body dementia and Parkinson's disease. This is the first demonstration of CD3 immunoreactivity in neurodegenerative diseases and raises interesting possibilities in terms of disease pathogenesis.
CD3 is a polypeptide complex comprised of four distinct chains (CD3c, CD3d, CD3e, and CD3f) associated with the T cell receptor (TCR), and has been demonstrated in T cells and natural killer cells (Kuhns et al. 2006) . The CD3 subunits are structurally related members of the immunoglobulin superfamily containing a single extracellular immunoglobulin domain, encoded by closely linked genes on chromosome 11. The CD3 components have long cytoplasmic tails which associate with cytoplasmic signal transduction molecules. The transmembrane region of the CD3 chains contains a negatively charged aspartic acid which allows these chains to associate with the positively charged TCR chains (TCRa and TCRb). The intracellular tails of CD3 complexes possess a single conserved motif known as an immunoreceptor tyrosine-based activation motif (ITAM), essential to the signaling capability of the TCR. CD3 may be a factor influencing TCR induced growth arrest, cell survival, and proliferation. After the TCR recognizes an antigen, major histocompatibility complex (MHC) its associated CD3 complex functions as a signal transducer, activating the signaling cascade of the T cell (Abbas et al. 2007) .
While previously restricted to the hematopoietic system, the CD3 molecule, and in particular the CD3f subunit, has been implicated as a product of neuronal metabolism in the setting of neurodevelopment. CD3f deficient mice show arrest of intrathymic T cell differentiation as expected (Malissen et al. 1993 ), but, in addition, show marked abnormalities in retinal ganglion cell projection to the lateral geniculate nucleus (Huh et al. 2000) . Additionally, defects in synaptic plasticity with alterations in long term potentiation have been demonstrated in CD3f deficient mice (Barco et al. 2005) . Taken together, CD3f appears to play a key role in neurodevelopment and synaptic plasticity.
Our finding that CD3 expression is altered, favoring accumulation within poorly soluble intraneuronal inclusions, shows a parallel with a-synuclein, the major protein component of Lewy bodies (Jellinger 2008) . Like CD3, asynuclein plays a major role in neurodevelopment, particularly development of the forebrain, as well as synaptic plasticity, and its alteration with age and disease is considered a major pathogenic factor in the progression of Parkinson's disease (Lee and Trojanowski 2006) . Thus, a common process appears to be emerging in Parkinson's disease pathogenesis, that is, an aberrant return of neurodevelopmental and synaptic processes, associated with progressive neurodegeneration. This also parallels other studies from our laboratory, indicating aberrant re-entry of neurons into the cell cycle during neurodegenerative processes (Chou et al. 2001; McShea et al. 2007; Previll et al. 2007; Zhu et al. 2008; Lee et al. 2009 ), cycling neuroblasts being critical to neurodevelopment. While the implications of these general processes in the treatment of Parkinson's disease and Lewy body dementia remain to be elucidated further studies exploring the parallels between aberrant neurodevelopment and neurodegeneration are warranted and may lead to novel therapeutic opportunities (Woods et al. 2007 ).
In conclusion, in this study we demonstrated a striking CD3 immunoreactivity in Lewy bodies and Lewy neurites in subjects with Parkinson's disease and Lewy body dementia. This is the first description of this antigen outside of the hematopoietic system in humans, and raises interesting possibilities in terms of the pathogenesis of neurodegenerative diseases.
